STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and moreWorldPing
Image via STAT.

What happened

Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions…

Key facts

  • Reported by STAT and published Fri, 11 Sep 2026 13:56:13 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field

  2. STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Related WorldPing coverage

9/11, 25 years on: 'A time for reflection about the way the world has gone'WorldPing
France 24

9/11, 25 years on: 'A time for reflection about the way the world has gone'

Twenty-five years after the ​deadliest attack on US soil, Americans will pause on Friday to commemorate the nearly 3,000 people killed when hijacked planes slammed into the World Trade Center, the Pentagon and a field in Pennsylvania.

Brief by WorldPing · Original reporting by France 24